Processa Pharmaceuticals Inc
$ 1.94
4.86%
24 Feb - close price
- Market Cap 4,395,600 USD
- Current Price $ 1.94
- High / Low $ 1.95 / 1.84
- Stock P/E N/A
- Book Value 2.76
- EPS -28.75
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.30 %
- ROE -2.71 %
- 52 Week High 19.62
- 52 Week Low 1.76
About
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients with unmet medical needs in the United States. The company is headquartered in Hanover, Maryland.
Analyst Target Price
$25.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-11 | 2025-05-08 | 2025-03-27 | 2024-10-30 | 2024-08-13 | 2024-05-10 | 2024-03-29 | 2023-11-13 | 2023-08-10 | 2023-05-15 | 2023-03-30 |
| Reported EPS | -0.07 | -0.25 | -0.3 | -0.74 | -1.03 | -1.01 | -1.11 | -1.7 | -0.08 | -0.097 | -0.18 | -0.36 |
| Estimated EPS | -0.45 | -0.23 | -1.18 | -0.92 | -1 | -0.98 | -1.18 | -1.6 | -0.1 | -0.23 | -0.28 | -0.32 |
| Surprise | 0.38 | -0.02 | 0.88 | 0.18 | -0.03 | -0.03 | 0.07 | -0.1 | 0.02 | 0.133 | 0.1 | -0.04 |
| Surprise Percentage | 84.4444% | -8.6957% | 74.5763% | 19.5652% | -3% | -3.0612% | 5.9322% | -6.25% | 20% | 57.8261% | 35.7143% | -12.5% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.5 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCSA
2026-02-13 10:57:57
RedChip Companies will broadcast interviews with Processa Pharmaceuticals (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on its "RedChip Small Stocks, Big Money™" show on Bloomberg TV. Processa Pharmaceuticals will discuss its Next Generation Cancer (NGC) platform and Phase 2 study for advanced breast cancer. 60 Degrees Pharmaceuticals will talk about its FDA-approved antimalarial ARAKODA® and its plans to expand approval for babesiosis.
2026-02-05 02:29:49
RedChip Companies will broadcast interviews with Alliance Entertainment Holding Corp. (AENT) and Processa Pharmaceuticals, Inc. (PCSA) on its "RedChip Small Stocks, Big Money™" show this Saturday, January 10, at 7 p.m. ET on Bloomberg TV. Alliance Entertainment's Bruce Ogilvie will discuss the company's role in entertainment distribution and its growing portfolio, while Processa Pharmaceuticals' David Young will provide an update on their Next Generation Cancer platform and Phase 2 study of NGC-Cap for breast cancer. Both companies are clients of RedChip Companies.
2026-02-03 00:59:30
RedChip Companies will feature interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) on its sponsored Bloomberg TV show "RedChip Small Stocks, Big Money™" on Saturday, January 10, at 7 p.m. ET. Alliance Entertainment's Executive Chairman, Bruce Ogilvie, will discuss the company's position in entertainment and pop culture collectibles, its expanding partnerships, and strategic growth. David Young, President of Research and Development for Processa Pharmaceuticals, will provide an update on their Next Generation Cancer (NGC) platform, including preliminary Phase 2 data for NGC-Cap in breast cancer patients.
2026-02-01 09:31:26
RedChip Companies will feature interviews with Alliance Entertainment Holding Corp. (Nasdaq: AENT) and Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) on its "RedChip Small Stocks, Big Money™" show, a sponsored program airing on Bloomberg TV. Alliance Entertainment's Executive Chairman, Bruce Ogilvie, will discuss the company's position in the entertainment and pop culture collectibles market, its growing partnerships, and efforts to improve profitability. David Young, President of Research and Development for Processa Pharmaceuticals, will provide a clinical update on its Next Generation Cancer (NGC) platform, specifically a Phase 2 study for advanced or metastatic breast cancer, highlighting data suggesting increased efficacy and comparable safety.
2026-02-01 05:31:35
RedChip Companies will broadcast interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) on its "RedChip Small Stocks, Big Money™" show on Bloomberg TV. Alliance Entertainment will discuss its role in the entertainment and pop culture collectibles market, while Processa Pharmaceuticals will provide an update on its Next Generation Cancer (NGC) platform and Phase 2 study of NGC-Cap. The program is scheduled to air on Saturday, January 10, at 7 p.m. Eastern Time.
2026-01-31 07:00:35
RedChip Companies will feature interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) on its "RedChip Small Stocks, Big Money" show on Bloomberg TV. The show airs on Saturday, January 10, at 7 p.m. ET. Bruce Ogilvie of Alliance Entertainment will discuss the company's position in entertainment and collectibles, while David Young of Processa Pharmaceuticals will provide a clinical update on its NGC-Cap Phase 2 study for advanced breast cancer.
